Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Bank of Montreal Can

Bank of Montreal Can trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,351 shares of the company’s stock after selling 898 shares during the quarter. Bank of Montreal Can’s holdings in Neurocrine Biosciences were worth $5,417,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. The Manufacturers Life Insurance Company raised its stake in shares of Neurocrine Biosciences by 18.3% during the 4th quarter. The Manufacturers Life Insurance Company now owns 116,955 shares of the company’s stock worth $15,410,000 after buying an additional 18,070 shares during the period. Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of Neurocrine Biosciences by 3.5% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 252,565 shares of the company’s stock worth $34,834,000 after purchasing an additional 8,630 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Neurocrine Biosciences by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 9,710,328 shares of the company’s stock worth $1,279,433,000 after purchasing an additional 150,485 shares in the last quarter. Perceptive Advisors LLC increased its position in shares of Neurocrine Biosciences by 70.1% during the fourth quarter. Perceptive Advisors LLC now owns 270,794 shares of the company’s stock worth $35,680,000 after purchasing an additional 111,552 shares in the last quarter. Finally, Van ECK Associates Corp increased its position in shares of Neurocrine Biosciences by 1,325.5% during the first quarter. Van ECK Associates Corp now owns 92,243 shares of the company’s stock worth $12,722,000 after purchasing an additional 85,772 shares in the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences Trading Down 0.9 %

NBIX opened at $114.15 on Wednesday. The stock’s 50-day moving average price is $134.89 and its 200 day moving average price is $137.25. Neurocrine Biosciences, Inc. has a 12-month low of $103.63 and a 12-month high of $157.98. The firm has a market cap of $11.49 billion, a price-to-earnings ratio of 31.21 and a beta of 0.37.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Thursday, August 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.15 by ($0.52). Neurocrine Biosciences had a return on equity of 14.86% and a net margin of 16.00%. The firm had revenue of $590.20 million for the quarter, compared to analyst estimates of $545.98 million. During the same period in the previous year, the company posted $0.95 EPS. Neurocrine Biosciences’s revenue was up 30.4% on a year-over-year basis. On average, research analysts forecast that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on NBIX. Citigroup boosted their price target on Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Barclays dropped their price target on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. StockNews.com upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Sunday, August 4th. JPMorgan Chase & Co. upped their target price on Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Finally, HC Wainwright restated a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a report on Thursday, August 29th. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $162.20.

Insider Buying and Selling

In related news, insider Julie Cooke sold 12,632 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $153.26, for a total transaction of $1,935,980.32. Following the transaction, the insider now owns 18,202 shares of the company’s stock, valued at approximately $2,789,638.52. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Neurocrine Biosciences news, Director Gary A. Lyons sold 930 shares of the stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $150.03, for a total value of $139,527.90. Following the sale, the director now owns 119,047 shares of the company’s stock, valued at approximately $17,860,621.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Julie Cooke sold 12,632 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $153.26, for a total value of $1,935,980.32. Following the completion of the sale, the insider now directly owns 18,202 shares in the company, valued at approximately $2,789,638.52. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 61,798 shares of company stock valued at $9,274,196. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.